Enliven (ELVN) CSO reports 7,000-share sale under 10b5-1; holdings remain >933k

Q: What transactions did Joseph Lyssikatos report on Form 4 for ELVN?

The Form 4 reports two sales on 09/19/2025 totaling 7,000 shares : 4,870 shares at a weighted average of $19.1095 and 2,130 shares at a weighted average of $20.016 .

Q: Who signed the Form 4?

The Form 4 was signed by Ben Hohl , by power of attorney, on 09/23/2025 .

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos reported two open-market sales of company common stock executed under a Rule 10b5-1 trading plan. On 09/19/2025 he sold 4,870 shares at a weighted average price of $19.1095 and 2,130 shares at a weighted average price of $20.016, for a total of 7,000 shares sold. The filings state the trades were executed in multiple transactions with sale prices ranging from $18.94 to $20.0469. After these sales the reporting person’s beneficial ownership is reported as 933,188 shares held indirectly through The Lyssikatos Revocable Trust, for which he is trustee. The Form 4 was signed by an attorney-in-fact on 09/23/2025.

Positive

Disclosed under a Rule 10b5-1 plan, indicating the sales were pre-arranged and intended to comply with insider trading rules
Full Form 4 disclosure includes number of shares, weighted average prices, price ranges, and the indirect ownership vehicle
Reporting person offers to provide detailed per-trade sale information on request, increasing transparency

Negative

Insider sold 7,000 shares on 09/19/2025, which reduced reported beneficial ownership to 933,188 shares
Sales executed in multiple trades across price ranges, which may complicate immediate assessment of the precise timing and allocation of proceeds without requesting per-trade details

Insights

TL;DR: Routine disclosure of insider sales under a documented 10b5-1 plan; transparency is maintained.

The Form 4 shows a named officer executed sales pursuant to a Rule 10b5-1 plan adopted on November 15, 2024, which provides an affirmative defense under insider trading rules. The filing discloses the number of shares sold (7,000), the weighted average prices and price ranges, and the indirect ownership vehicle (a revocable trust). This level of disclosure aligns with good governance practices by documenting the plan date and offering to provide per-trade details on request. No derivative transactions or amendments to previously reported holdings are disclosed beyond the reported sales.

TL;DR: Officer sold 7,000 shares in multiple trades; reported holdings remain above 900k shares.

The reported sales consist of 4,870 shares at a weighted average of $19.1095 and 2,130 shares at a weighted average of $20.016 executed on 09/19/2025 under a 10b5-1 plan. The filer reports beneficial ownership of 933,188 shares held indirectly via a revocable trust. The filing includes granular price ranges ($18.94–$19.89 and $19.95–$20.0469) and commits to provide detailed per-trade allocation upon formal request. From a market-data perspective this is an insider liquidity event disclosed in compliance with Section 16 reporting requirements; the filing contains no other operational or financial metrics.

Insider Trade Summary

Net Seller: 7,000 shares ($135,697)

Net Sell 2 txns

Insider Lyssikatos Joseph P

Role CHIEF SCIENTIFIC OFFICER

Sold 7,000 shs ($136K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,870	$19.1095	$93K
Sale	Common Stock	2,130	$20.016	$43K

Holdings After Transaction: Common Stock — 935,318 shares (Indirect, See footnote)

Footnotes (1)

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024. This transaction was executed in multiple trades at prices ranging from $18.94 to $19.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee. This transaction was executed in multiple trades at prices ranging from $19.95 to $20.0469. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Form 4 Insider Transactions: What Each Field Means →

09/23/2025 - 05:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lyssikatos Joseph P

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER

80301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/19/2025		S⁽¹⁾		4,870	D	$19.1095⁽²⁾	935,318	I	See footnote⁽³⁾
Common Stock	09/19/2025		S⁽¹⁾		2,130	D	$20.016⁽⁴⁾	933,188	I	See footnote⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

2. This transaction was executed in multiple trades at prices ranging from $18.94 to $19.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

4. This transaction was executed in multiple trades at prices ranging from $19.95 to $20.0469. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Ben Hohl, by power of attorney	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What transactions did Joseph Lyssikatos report on Form 4 for ELVN?

The Form 4 reports two sales on 09/19/2025 totaling 7,000 shares: 4,870 shares at a weighted average of $19.1095 and 2,130 shares at a weighted average of $20.016.

Were the sales by the ELVN officer part of a prearranged plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.

How many ELVN shares does the reporting person own after the reported sales?

Following the reported transactions, beneficial ownership is reported as 933,188 shares, held indirectly through The Lyssikatos Revocable Trust.

Does the Form 4 provide per-trade sale prices for the reported transactions?

The Form 4 provides weighted average prices and price ranges ($18.94–$20.0469) and states the reporting person will provide per-trade details upon request by the SEC, the issuer, or a security holder.

Who signed the Form 4?

The Form 4 was signed by Ben Hohl, by power of attorney, on 09/23/2025.